|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...104105106107108109110111112113114...156157» |
- |||| blisibimod (A-623) / Anthera Pharma
Trial completion: A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321 (clinicaltrials.gov) - Feb 10, 2014
P2, N=382, Completed, Sponsor: Anthera Pharmaceuticals
Active, not recruiting --> Completed
- Trial completion: Magnetic Resonance Spectroscopy, Perfusion and Diffusion Tensor Imaging in Neuropsychiatric Lupus (clinicaltrials.gov) - Feb 10, 2014
P=N/A, N=75, Completed, Sponsor: University of Michigan
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial termination: Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults (clinicaltrials.gov) - Feb 10, 2014
P2, N=23, Terminated, Sponsor: Exsulin Corporation
Active, not recruiting --> Completed Suspended --> Terminated; Preserve clinical supplies
- Enrollment change: Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults (clinicaltrials.gov) - Feb 10, 2014
P2, N=23, Terminated, Sponsor: Exsulin Corporation
Suspended --> Terminated; Preserve clinical supplies N=30 --> 23
- hydroxyurea / Generic mfg.
Trial termination: Hydroxyurea in Primary Progressive Multiple Sclerosis (clinicaltrials.gov) - Feb 9, 2014
P2/3, N=33, Terminated, Sponsor: S. Andrea Hospital
N=30 --> 23 Recruiting --> Terminated; No efficacy (interim.analysis)
- Trial termination: FLORIMS: Flupirtine as Oral Treatment in Multiple Sclerosis (clinicaltrials.gov) - Feb 9, 2014
P2, N=30, Terminated, Sponsor: Charite University, Berlin, Germany
Recruiting --> Terminated; No efficacy (interim.analysis) Completed --> Terminated
- hydroxyurea / Generic mfg.
Enrollment change: Hydroxyurea in Primary Progressive Multiple Sclerosis (clinicaltrials.gov) - Feb 9, 2014
P2/3, N=33, Terminated, Sponsor: S. Andrea Hospital
Completed --> Terminated N=60 --> 33
- |||| itacitinib (INCB039110) / Incyte
Trial completion: A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 9, 2014
P2, N=106, Completed, Sponsor: Incyte Corporation
N=60 --> 33 Recruiting --> Completed
- pateclizumab (RG7416) / Roche
Trial completion, Combination therapy: A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 9, 2014
P2, N=211, Completed, Sponsor: Genentech
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
MRI: SCORE: A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate (clinicaltrials.gov) - Feb 9, 2014
P3, N=185, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Interferon ß-1b Treatment by Cyclical Administration (clinicaltrials.gov) - Feb 9, 2014
P2/3, N=60, Completed, Sponsor: S. Andrea Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- tacrolimus XR / Generic mfg.
Enrollment change: Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis (clinicaltrials.gov) - Feb 9, 2014
P3, N=0, Withdrawn, Sponsor: Sun Yat-sen University
Active, not recruiting --> Completed N=20 --> 0
- Lumigan (bimatoprost) / Senju, AbbVie
New P4 trial: Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) (clinicaltrials.gov) - Feb 9, 2014
P4, N=31, Not yet recruiting, Sponsor: Cardiff University
- |||||||||| Lantus (insulin glargine) / Sanofi, Lusduna (insulin glargine biosimilar) / Samsung
New P3 trial: A Study of the Safety and Efficacy of MK-1293 Compared to Lantus (clinicaltrials.gov) - Feb 9, 2014
P3, N=500, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||| Lusduna (insulin glargine biosimilar) / Samsung
New P1 trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005) (clinicaltrials.gov) - Feb 9, 2014
P1, N=130, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment open, Combination therapy, Monotherapy: ACT-MOVE: A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent (clinicaltrials.gov) - Feb 9, 2014
P3, N=160, Recruiting, Sponsor: Hoffmann-La Roche
N=20 --> 0 Not yet recruiting --> Recruiting
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed, Monotherapy: ARMONIA: An Observational Study of Biologic Drugs in Monotherapy or Combination With DMARDs in Italian Clinical Practice and the Efficacy and Safety of RoActemra/Actemra (Tocilizumab) Monotherapy in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 9, 2014
P=N/A, N=304, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed: Observational Study of Tocilizumab in Participants With Rheumatoid Arthritis in Australia (clinicaltrials.gov) - Feb 9, 2014
P=N/A, N=37, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | gevokizumab (VPM087) / Novartis
Trial completion: Effects of XOMA 052 on Insulin Production in Type 1 Diabetes (clinicaltrials.gov) - Feb 9, 2014
P2, N=22, Completed, Sponsor: University of Zurich
Recruiting --> Active, not recruiting Recruiting --> Completed
- Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study (clinicaltrials.gov) - Feb 9, 2014
P3, N=7, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Active, not recruiting --> Completed
- Trial termination: MENT-APL-O: Comparative Prevalence of Psychiatric Manifestations in Purely Obstetrical Antiphospholipid Syndrome (clinicaltrials.gov) - Feb 6, 2014
P=N/A, N=20, Terminated, Sponsor: Centre Hospitalier Universitaire de Nīmes
Active, not recruiting --> Completed Recruiting --> Terminated; Impossible to include patients at a correct rate; patients don't want to come back so they refuse participation.
- Enrollment change: MENT-APL-O: Comparative Prevalence of Psychiatric Manifestations in Purely Obstetrical Antiphospholipid Syndrome (clinicaltrials.gov) - Feb 6, 2014
P=N/A, N=20, Terminated, Sponsor: Centre Hospitalier Universitaire de Nīmes
Recruiting --> Terminated; Impossible to include patients at a correct rate; patients don't want to come back so they refuse participation. N=1000 --> 20
- Trial completion: Rehabilitation in Multiple Sclerosis: Influence of Exercise on Development of Insulin Resistance, Muscle Power and Aerobic Capacity (clinicaltrials.gov) - Feb 6, 2014
P=N/A, N=45, Completed, Sponsor: Hasselt University
N=1000 --> 20 Active, not recruiting --> Completed
- ||| toreforant (JNJ-38518168) / J&J
Enrollment closed: A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate (clinicaltrials.gov) - Feb 5, 2014
P2, N=272, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Benlysta (belimumab) / GSK
Enrollment closed: BLISS-SC: A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Feb 5, 2014
P3, N=816, Active, not recruiting, Sponsor: Human Genome Sciences Inc., a GSK Company
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| mavrilimumab (KPL-301) / Kiniksa
Enrollment change: A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 5, 2014
P2, N=172, Recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting N=120 --> 172
- |||||||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
New P3 trial: SARIL-RA-EASY: To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 5, 2014
P3, N=200, Recruiting, Sponsor: Sanofi
- || staphylococcal protein A (PRTX-100) / Protalex
Enrollment closed, Combination therapy: SPARTA: Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 5, 2014
P1, N=64, Active, not recruiting, Sponsor: Protalex, Inc.
N=120 --> 172 Recruiting --> Active, not recruiting
- LAPS-Insulin (HM12460A) / Hanmi
Enrollment closed: A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A (clinicaltrials.gov) - Feb 5, 2014
P1, N=48, Active, not recruiting, Sponsor: Hanmi Pharmaceutical Company Limited
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||||| insulin peglispro (LY2605541) / Eli Lilly
Trial completion: IMAGINE 3: A Study in Participants With Type I Diabetes Mellitus (clinicaltrials.gov) - Feb 5, 2014
P3, N=1113, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment open: GotNet Study, The Gothenburg Nurse-led Tight Control Study (clinicaltrials.gov) - Feb 4, 2014
P=N/A, N=120, Recruiting, Sponsor: Vastra Gotaland Region
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Havrix (hepatitis A vaccine, inactivated) / GSK
Enrollment open: Immunogenicity and Safety of Vaccinations in Immunocompromised Persons (clinicaltrials.gov) - Feb 4, 2014
P=N/A, N=745, Recruiting, Sponsor: University of Zurich
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion, Combination therapy: FOLVARI: Study of Different Doses of Folic Acid in Combination With Methotrexate in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 4, 2014
P4, N=100, Completed, Sponsor: Postgraduate Institute of Medical Education and Research
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Biomarker, Trial completion: Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients (clinicaltrials.gov) - Feb 4, 2014
P=N/A, N=46, Completed, Sponsor: Columbia University
Recruiting --> Completed Recruiting --> Completed
- Trial completion: Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages (clinicaltrials.gov) - Feb 3, 2014
P1, N=6, Completed, Sponsor: Profil Institut f
Recruiting --> Completed Not yet recruiting --> Completed
- Trial completion: Treatment of Patients With Newly Onset of Type 1 Diabetes With Mesenchymal Stem Cells (clinicaltrials.gov) - Feb 3, 2014
P=N/A, N=20, Completed, Sponsor: Uppsala University Hospital
Not yet recruiting --> Completed Recruiting --> Completed
- || Rebif (human IFN-β-1a) / EMD Serono
Enrollment change: EMR200136_550: Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients (clinicaltrials.gov) - Feb 2, 2014
P=N/A, N=515, Active, not recruiting, Sponsor: Merck KGaA
Recruiting --> Completed N=346 --> 515
- Enrollment change: Group Balance Training for People With Multiple Sclerosis (clinicaltrials.gov) - Feb 2, 2014
P=N/A, N=87, Completed, Sponsor: Örebro County Council
N=346 --> 515 N=70 --> 87
- ||| Rebif (human IFN-β-1a) / EMD Serono
Enrollment change: CHOLINE: A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly (clinicaltrials.gov) - Feb 2, 2014
P2, N=129, Active, not recruiting, Sponsor: Merck KGaA
N=70 --> 87 N=250 --> 129
- || Rebif (human IFN-β-1a) / EMD Serono
Enrollment closed: EMR200136_550: Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients (clinicaltrials.gov) - Feb 2, 2014
P=N/A, N=515, Active, not recruiting, Sponsor: Merck KGaA
N=250 --> 129 Recruiting --> Active, not recruiting
- ||| Rebif (human IFN-β-1a) / EMD Serono
Enrollment closed: CHOLINE: A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly (clinicaltrials.gov) - Feb 2, 2014
P2, N=129, Active, not recruiting, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: Group Balance Training for People With Multiple Sclerosis (clinicaltrials.gov) - Feb 2, 2014
P=N/A, N=87, Completed, Sponsor: Örebro County Council
Recruiting --> Active, not recruiting Recruiting --> Completed
- | apilimod (STA-5326) / Madrigal Pharma
Trial completion: A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes (clinicaltrials.gov) - Feb 2, 2014
P2, N=35, Completed, Sponsor: Synta Pharmaceuticals Corp.
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| AcellBia (rituximab biosimilar) / Biocad, Kocak Farma
Enrollment change: BIORA: Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 2, 2014
P3, N=308, Recruiting, Sponsor: Biocad
Active, not recruiting --> Completed N=160 --> 308
- ||||| blisibimod (A-623) / Anthera Pharma
Trial initiation date: MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP (clinicaltrials.gov) - Jan 30, 2014
P2/3, N=60, Not yet recruiting, Sponsor: Anthera Pharmaceuticals
N=160 --> 308 Initiation date: Dec 2013 --> Dec 2014
- ||| Rebif (human IFN-β-1a) / EMD Serono
Trial initiation date: EMR200136-549: Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a (clinicaltrials.gov) - Jan 30, 2014
P2, N=80, Recruiting, Sponsor: Merck KGaA
Initiation date: Dec 2013 --> Dec 2014 Initiation date: Oct 2011 --> Apr 2012
- |||||||||| blisibimod (A-623) / Anthera Pharma
New P3 trial: BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy (clinicaltrials.gov) - Jan 30, 2014
P3, N=150, Not yet recruiting, Sponsor: Anthera Pharmaceuticals
- ||| blisibimod (A-623) / Anthera Pharma
Trial initiation date: BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis (clinicaltrials.gov) - Jan 30, 2014
P2, N=100, Not yet recruiting, Sponsor: Anthera Pharmaceuticals
Initiation date: Oct 2011 --> Apr 2012 Initiation date: Dec 2013 --> Dec 2014
- || Rebif (human IFN-?-1a) / EMD Serono
Trial initiation date, HEOR: MusiClock: An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF) (clinicaltrials.gov) - Jan 30, 2014
P=N/A, N=65, Completed, Sponsor: Merck KGaA
Initiation date: Dec 2013 --> Dec 2014 Initiation date: Nov 2009 --> Nov 2010
- | ASP2408 / Astellas
New P1 trial: A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate (clinicaltrials.gov) - Jan 30, 2014
P1, N=24, Completed, Sponsor: Astellas Pharma Global Development, Inc.